BioCentury
ARTICLE | Clinical News

Syros' SY-1425 plus Vidaza leads to 63% ORR in biomarker-positive AML cohort

December 14, 2018 6:35 PM UTC

Syros Pharmaceuticals Inc. (NASDAQ:SYRS) reported Phase II data from a cohort of eight evaluable newly diagnosed, biomarker-positive acute myelogenous leukemia (AML) patients showing that tamibarotene (SY-1425) plus Vidaza azacitidine from Celgene Corp. (NASDAQ:CELG) led to an overall response rate (ORR) of 63%. Data were presented at the American Society of Hematology (ASH) meeting in San Diego.

The responses included three complete responses (CRs), one CR with incomplete blood count recovery (CRi) and a morphologic leukemia-free state (MLFS) in one patient. The eight patients in the cohort were positive for the retinoic acid receptor α (RARA) and/or interferon regulatory factor 8 (IRF8) biomarkers and were ineligible for standard chemotherapy...